Investors

Investors

Company Information

 

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal and multi-specific antibodies that modulate targets of interest, as well as allogeneic cell therapies through its subsidiary AgenTus therapeutics. In addition, the Company’s cancer vaccine program includes proprietary individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory antibodies, cell therapies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with BMS, Gilead, Merck and Incyte to discover and develop multiple checkpoint antibodies.

Press Releases
Jul 26, 2021
Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to

btn News

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

btn Stock

SEC Filings

Form Description Filing date View
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

Data provided by Kaleidoscope.

btn SEC

Events and Presentations

btn Events